Navigation Links
Insmed Announces First Quarter 2011 Financial Results
Date:5/10/2011

nce of $104.9 million, which will continue to drive our development of ARIKACE®."

Financial Results:For the first quarter of 2011, Insmed posted a net loss attributable to common stockholders of $16.1 million, or $0.85 per share – basic and diluted, compared to net income of 0.1 million, or $0.01 per share – basic and diluted, for the three months ended March 31, 2010.  The net loss attributable to common stockholders in 2011 includes the conversion of the Series B Conditional Convertible Preferred Stock, and a non-cash charge for the beneficial conversion feature of the Series B Preferred Stock in the amount of $9.2 million.  When issuing debt or equity securities that are convertible into common stock at a discount from the fair value of the common stock at the date the debt or equity financing is committed, a company is required to record a beneficial conversion feature ("BCF") charge in accordance with Accounting Standards Codification 470-20.  This BCF of $9.2 million reduced net income available to holders of our common shares and, in turn, reduced our earnings per common share on a basic and diluted basis, by $0.48.  The charge represents the $1.00 difference between the conversion price of the preferred stock of $7.10 per share and its carrying value of $6.10 per share.  The carrying value of the preferred stock was based on its fair value at issuance, which was estimated using the common stock price reduced for a lack of marketability between the issuance date and the anticipated date of conversion.

Revenues were $1.6 million, as compared to $1.9 million for the quarter ended March 31, 2010.  The reduction in revenue was primarily attributable to $0.6 million in lower cost recovery from our IPLEX™ Expanded Access Program in Europe, which was partially offset by $0.3 million in licensing fees received during the most recent quarter.  The reduced IPLEX™ cost recovery was due to t
'/>"/>

SOURCE Insmed Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Insmed to Host 2011 First Quarter Earnings Conference Call
2. Insmed Announces European Medicines Agency Acceptance of Its Pediatric Investigation Plan for ARIKACEā„¢ in the Cystic Fibrosis Pseudomonas Indication
3. One-for-10 Reverse Stock Split of Insmed Common Stock Becomes Effective
4. Insmed Shareholders Approve Conversion of Series B Conditional Convertible Preferred Stock and Reverse Stock Split
5. Insmed to Host Fourth Quarter and 2010 Year-End Earnings Conference Call
6. NASDAQ Grants Insmed Incorporated 180-Day Extension to Regain Compliance with Minimum Bid Price Rule
7. Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2010
8. Insmed to Host Third Quarter 2010 Conference Call
9. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
10. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
11. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Zafgen, Inc., a leading biopharmaceutical ... severely obese patients, today announced initial results from ... inhibitor of methionine aminopeptidase 2 (MetAP2), in patients ... genetic obesity.  These results showed improvements in body ...
(Date:1/14/2014)... 2014 InformEx, North America,s leading ... will hold the 30 th edition of its annual ... Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... fine chemical and specialty chemical companies will take part in ...
(Date:1/14/2014)... LEESBURG, Va. , Jan. 14, 2014 Animal Emergency Critical ... in Leesburg, Virginia is the first in ... hyperbaric oxygen chamber. Dr. Susan M. Barnes ... years. Dr. Barnes and husband, Dr. Cole Taylor , are ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... PRO-DEX, INC. (Nasdaq: PDEX ) invites investors and ... fiscal 2011 fourth quarter and full-year financial results. ... the internet on Wednesday, September 14, 2011 at 4:30 p.m. ... by visiting the Company,s website at www.pro-dex.com and ...
... (NASDAQ: PCYC ), a biopharmaceutical company focused ... the treatment of cancer and immune mediated diseases, today ... fourth fiscal quarter and fiscal year ended June 30, ... 12, 2011.  The company will conduct a conference call ...
Cached Medicine Technology:Pro-Dex, Inc. Announces Fiscal 2011 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast 2Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call 2
(Date:4/20/2014)... harmful effects in children, codeine continues to be prescribed ... UCSF Benioff Children,s Hospital San Francisco. , As reported ... include changing provider prescription behaviors to promote the use ... hydrocodone. , "Despite strong evidence against the use of ... to large numbers of them each year," said Sunitha ...
(Date:4/18/2014)... in The Gerontologist reports that ... with a decrease in anxiety about death and increases ... their lives. In particular, listening to gospel music is ... an increase in sense of control. , These associations ... and individuals of both low- and high-socioeconomic status. , ...
(Date:4/18/2014)... a brain-related discovery that could revolutionize doctors, perception ... opens up the possibility that environmental and/or genetic ... activity that the researchers have identified as helping ... Neuroscience has just published a paper about ... of psychology and his doctoral student John Gaspar, ...
(Date:4/17/2014)... chronic inflammation in non-cancerous prostate tissue may have nearly ... those with no inflammation, according to results of a ... Kimmel Cancer Center. , The link between persistent inflammation ... high-grade prostate cancer those with a Gleason score ... the most aggressive and rapidly growing prostate cancers. , ...
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary research ... Kenis in the Institute of Genomic Biology (IGB) ... Urbana-Champaign describe their recent work on subcellular redox ... cell functions including energy metabolism, signaling, and transcriptional ... normal cellular behavior, redox status has been recognized ...
Breaking Medicine News(10 mins):Health News:UCSF study finds codeine often prescribed to children, despite available alternatives 2Health News:Religious music brings benefit to seniors' mental health 2Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2
... , , , MANHATTAN, Kan., ... work of a K-State researcher are making headway in the effort ... Juergen Richt is a Regents Distinguished Professor at K-State,s College of ... work at K-State and with outside collaborators is revealing the characteristics ...
... Experts urge parents to get their kids, eyes checked regularly ... percent of kids aged 12 to 17 have trouble seeing ... the nearly 1,500 children in the survey, more than 25 ... though 45 percent of them wore some type of prescription ...
... , CHESTNUT HILL, Mass., Aug. 3 SkinCare ... live Artefill patient demonstration at the American Academy of Dermatology Summer ... collagen filler for the correction of smile lines and was one ... 31st. , , "Over the past several years ...
... , ALLEGAN, Mich., Aug. 3 Perrigo Company (Nasdaq: ... Pharmaceutical Industries Ltd. (Nasdaq: TEVA ) (previously Barr Laboratories ... Administration to market Triamcinolone Acetonide Nasal Spray containing a paragraph IV ... complete ANDA with a Paragraph IV certification for NASACORT AQ. The ...
... equipment alone is responsible for an increased number of ... to a study performed at San Luis Diagnostic Center ... that there was a significant increase in the number ... to digital mammography. The number of cancers detected prior ...
... in French . Heavy drinkers of ... cancer than the population at large, says a group of ... in the highest consumption category increased their risk of developing ... cancer by 50%. In all, the researchers found ...
Cached Medicine News:Health News:K-State Researcher, Collaborators Study Virulence of Pandemic H1N1 Virus; Work at K-State Would Protect Pig Industry If the Virus Jumps to Swine Populations 2Health News:Leading Boston Dermatologist Performs Live Artefill Patient Demonstration at American Academy of Dermatology Summer Meeting 2Health News:Perrigo Announces FDA Approval for Generic Version of NASACORT(R) AQ 2Health News:Perrigo Announces FDA Approval for Generic Version of NASACORT(R) AQ 3Health News:Heavy drinkers face significantly increased cancer risk 2
... Lomb PMMA Anterior Chamber Intraocular Lenses are ... in patients 60 years of age or ... removed by primary intracapsular cataract extraction; or ... a structural reason that the anterior chamber ...
... Amvisc Plus is the preferred viscoelastic ... viscoelastic that reliably works from the start ... unique, moderately cohesive profile of this viscoelastic ... vacuum forces associated with phacoemulsification remove only ...
... ENDOGEL is a sterile, non-pyrogenic solution ... is supplied in a disposable single ... fitting, delivering 0,85 ml. Sodium ... of repetitive chains of disaccharides, glucoronate, ...
... a sterile, non-pyrogenic, transparent viscoelastic preparation ... molecular weight (average molecular weight 4 ... 23 mg/mL of sodium hyaluronate 5000, ... N-acetylglucosamine and sodium glucuronate linked by ...
Medicine Products: